Ovarian Cancer Clinical Trial

Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial

Summary

This phase II trial compares selumetinib plus olaparib to selumetinib alone in women with endometrial or ovarian cancer that has come back (recurrent) or that remains despite treatment (persistent) and harbors a mutation in the RAS pathway. Selumetinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Olaparib is an inhibitor of PARP, an enzyme that helps repair deoxyribonucleic acid (DNA) when it becomes damaged. Blocking PARP may help keep tumor cells from repairing their damaged DNA, causing them to die. PARP inhibitors are a type of targeted therapy. The addition of olaparib to selumetinib could increase the percentage of tumors that shrink as well as lengthen the time that the tumors remain stable (without progression) as compared to selumetinib alone.

View Full Description

Full Description

PRIMARY OBJECTIVES:

I. Compare progression free survival of combination of olaparib and selumetinib sulfate (selumetinib) to selumetinib alone in patients with RAS mutant ovarian cancer. (Cohort 1) II. Compare progression free survival of combination of olaparib and selumetinib to selumetinib alone in patients with RAS mutant endometrial cancer. (Cohort 2)

SECONDARY OBJECTIVES:

I. Determine safety of both arms per Common Terminology Criteria for Adverse Events (CTCAE) version (v)5.0.

II. Compare objective response rate per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 between the two arms.

III. Determine rate of objective response per RECIST 1.1 in those patients that crossover from the single agent arm to the combination arm.

IV. Report duration of response of the two treatment arms. V. Collect tissue and provide it to the ComboMATCH Registration protocol to assess concordance between the diagnostic tumor mutation profile generated by the designated laboratories, the pre-treatment biopsy mutation profile, and the pre-treatment circulating tumor (ct)DNA mutation profile from plasma, as described in ComboMATCH Registration protocol. For this treatment substudy, the outcome objective will be to report the proportion of cases providing sufficient tissue for that integrated scientific activity in the ComboMATCH Registration protocol.

TRANSLATIONAL OBJECTIVE:

I. To assess association of baseline genomic and transcriptomic status with response and resistance to therapy.

OUTLINE: Patients in both cohorts are randomized to 1 of 2 arms.

ARM I: Patients receive selumetinib orally (PO) twice daily (BID) and olaparib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo a tumor biopsy and blood collection during screening and on study, as well as echocardiogram (ECHO) or multigated acquisition (MUGA), and computed tomography (CT) scans throughout the trial. Patients may undergo bone marrow aspiration or biopsy as clinically indicated.

ARM II: Patients receive selumetinib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients who experience progression may elect to cross over to Arm I provided they have not had dose limiting toxicities to monotherapy selumetinib. Patients also undergo a tumor biopsy and blood collection during screening and on study, as well as ECHO or MUGA, and CT scans throughout the trial. Patients may undergo bone marrow aspiration or biopsy as clinically indicated.

After completion of study treatment, patients are followed up every 3 months for 2 years and then every 6 months for 3 years.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Patient must have enrolled onto EAY191 and must have been given a treatment assignment to ComboMATCH to EAY191-N4 based on the presence of an actionable mutation as defined in EAY191
Patients must be enrolled on the ComboMATCH Master Registration Trial EAY191

Patients must have RAS pathway mutations as determined by the ComboMATCH screening assessment

Cohort 1: Patients with histologically confirmed RAS pathway mutant ovarian, primary peritoneal, or fallopian tube ("ovarian") cancer (activating mutations in KRAS, NRAS, HRAS, BRAF, MEK1, MEK2, or inactivating mutations in NF1)
Cohort 2: Patients with histologically confirmed RAS pathway mutant endometrial cancer (activating mutations in KRAS, NRAS, HRAS, BRAF, MEK1, MEK2, or inactivating mutations in NF1).
Patients must have disease that can be safely biopsied and agree to a pre-treatment biopsy, if disease cannot be safely biopsied, or have archival tissue available from within 12 months prior to registration on the ComboMATCH Registration Trial (EAY191)
Patients must have progressed after first-line treatment for recurrent or persistent disease
Patients with ovarian cancer should not be eligible for further platinum-based therapy
Patients with endometrial cancer must have received or been offered an immune oncology agent (alone or in combination with lenvatinib) unless there are existing contraindications for immune oncology agents or lenvatinib
Patients may have received unlimited prior therapy

Patients must have measurable and biopsiable disease. Measurable disease is defined by RECIST 1.1 as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded). Each lesion must be > 10 mm when measured by CT, magnetic resonance imaging (MRI) or caliper measurement by clinical exam; or > 20 mm when measured by chest x-ray. Lymph nodes must be > 15 mm in short axis when measured by CT or MRI

Patients must have at least one "target lesion" separate from the lesion to be biopsied to be used to assess response on this protocol as defined by RECIST version 1.1. Tumors within a previously irradiated field will be designated as "non-target" lesions unless progression is documented or a biopsy is obtained to confirm persistence at least 90 days following completion of radiation therapy
Prior therapy must have been completed at least four weeks prior to registration
Age >= 18
Eastern Cooperative Oncology Group (ECOG) Performance Status of 0, 1 or 2
Hemoglobin (Hgb) >= 9.5 g/dL with no blood transfusion in the past 28 days (within 14 days prior to registration)
Platelets >= 100,000/mcl (within 14 days prior to registration)
Absolute neutrophil count (ANC) >= 1,500/mcl (within 14 days prior to registration)
Patients must have creatinine clearance estimated of >= 50 mL/min using the Cockcroft-Gault equation or based on a 24 hour urine test (within 14 days prior to registration)
Total bilirubin level =< 1.5 x institutional upper limit of normal (ULN) or =< 3 x ULN in the presence of documented Gilbert's syndrome (unconjugated hyperbilirubinemia) (within 14 days prior to registration)
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3 x ULN (within 14 days prior to registration)
Patients must be able to swallow and retain oral medications and be without gastrointestinal illnesses that would preclude absorption of selumetinib or olaparib
Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, patients should be class 2B or better

Women of childbearing potential (WOCBP) must agree to use two forms of birth control (hormonal or barrier method of birth control; abstinence) during the study and for 12 weeks after completing treatment

Non-sterilized male partners of WOCBP (including males sterilized by a method other than bilateral orchidectomy e.g., vasectomy) who intend to be sexually active with a female partner must be using an acceptable method of contraception such as male condom plus spermicide (condom alone in countries where spermicides are not approved) from the time of screening throughout the total duration of the study and the drug washout period (at least 16 weeks after the last dose of study intervention) to prevent pregnancy in a partner. Periodic abstinence, the rhythm method, and the withdrawal method are not acceptable methods of contraception. Vasectomized (i.e., sterile) males are considered fertile and should still use a male condom plus spermicide as indicated above during the clinical study
Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial
Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months of registration are eligible for this trial

Patients with evidence of chronic hepatitis B virus (HBV) infection must have an undetectable HBV viral load on suppressive therapy, if indicated

Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load

Patients with new or progressive brain metastases (active brain metastases) or leptomeningeal disease are eligible if the treating physician determines that immediate central nervous system (CNS) specific treatment is not required and is unlikely to be required during the first cycle of therapy

Patients with treated brain metastases are eligible if follow-up brain imaging after CNS-directed therapy shows no evidence of progression
Extra caution should be taken with olaparib, as it crosses the blood brain barrier and can cause edema in brain metastases
The patient or a legally authorized representative must provide study-specific informed consent prior to study entry and, for patients treated in the United States (U.S.), authorization permitting release of personal health information

Exclusion Criteria:

Patients who have received any MEK inhibitors
Patients who have progressed while receiving a PARP inhibitor
Patients who have received chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to registration
Patients who have not recovered from adverse events due to prior anti-cancer therapy (i.e., have residual toxicities > grade 1) with the exception of alopecia
Patients with uncontrolled intercurrent illness
Patients with >= grade 2 neuropathy within 14 days of registration
Patients with severe (Child-Pugh C) liver dysfunction
Patients with a history of allergic reactions attributed to compounds of similar chemical or biologic composition to olaparib and selumetinib or any excipients thereof

Concomitant use of known strong (e.g., phenobarbital, enzalutamide, phenytoin, rifampicin, rifabutin, rifapentine, carbamazepine, nevirapine and St John's Wort) or moderate CYP3A inducers (e.g., bosentan, efavirenz, modafinil). The required washout period prior to starting olaparib is 5 weeks for enzalutamide or phenobarbital and 3 weeks for other agents

Supplementation with vitamin E greater than 100% of the daily recommended dose. Any multivitamin containing vitamin E must be stopped prior to study enrollment even if less than 100% of the daily recommended dosing for vitamin E
Vitamin E must not be taken in the 7 days prior to initiation of treatment with selumetinib
Concomitant use of known strong CYP3A inhibitors (e.g., itraconazole, telithromycin, clarithromycin, protease inhibitors boosted with ritonavir or cobicistat, indinavir, saquinavir, nelfinavir, boceprevir, telaprevir) or known moderate CYP3A inhibitors (e.g. ciprofloxacin, erythromycin, diltiazem, Fluconazole, verapamil). The required washout period prior to starting olaparib is at least 14 days or 5 half-lives (whichever is longer) before the first dose of study medication
Concomitant use of strong CYP2C19 inhibitors (e.g., ticlopidine) or moderate CYP2C19 inhibitors (e.g., omeprazole). The required washout period prior to starting selumetinib is at least 14 days or 5 half-lives (whichever is longer) before the first dose of study medication
Have received or are receiving an investigational medicinal product (IMP) or other systemic anti-cancer treatment (including chemotherapy, immunotherapy, targeted therapy, biologic therapy, tumor embolization, or monoclonal antibodies) within 4 weeks prior to registration, or within a period during which the IMP or systemic target treatment has not been cleared from the body (e.g., a period of 5 'half-lives'), whichever is longer
Known myelodysplastic syndrome/acute myeloid leukemia or with features suggestive of myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML)
Patients who have had previous organ transplant, allogenic bone marrow transplant or double umbilical cord blood transplantation
Patients who have had whole blood transfusion within 28 days prior to registration

Patients with ophthalmological conditions as follows:

Current or past history of retinal pigment epithelial detachment/central serous retinopathy or retinal vein occlusion.
Intraocular pressure >21 mmHg (or ULN adjusted by age) or uncontrolled glaucoma (irrespective of intraocular pressure [IOP]). Subjects with known glaucoma and increased IOP who do not have meaningful vision (light perception only or no light perception) and are not experiencing pain related to the glaucoma, may be eligible after discussion with the study chair
Patients with any other significant abnormality on ophthalmic examination should be discussed with the study chair for potential eligibility
Ophthalmological findings secondary to long-standing optic pathway glioma (such as visual loss, optic nerve pallor or strabismus) or longstanding orbito-temporal plexiform neurofibroma (PN) (such as visual loss, strabismus) will NOT be considered a significant abnormality for the purposes of the study

Patients with severe, active co-morbidity defined as any of the following:

History and/or confirmed pneumonitis
Uncontrolled hypertension (blood pressure [BP] >= 150/90 mmHg despite medical therapy)
Acute coronary syndrome within 6 months prior to registration
Uncontrolled atrial fibrillation
Known family history of long QT syndrome
Women who are pregnant or unwilling to discontinue nursing

Study is for people with:

Ovarian Cancer

Phase:

Phase 2

Estimated Enrollment:

165

Study ID:

NCT05554328

Recruitment Status:

Recruiting

Sponsor:

National Cancer Institute (NCI)

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 205 Locations for this study

See Locations Near You

University of Alabama at Birmingham Cancer Center
Birmingham Alabama, 35233, United States More Info
Site Public Contact
Contact
205-934-0220
[email protected]
Rebecca C. Arend
Principal Investigator
University of South Alabama Mitchell Cancer Institute
Mobile Alabama, 36688, United States More Info
Site Public Contact
Contact
251-445-9870
[email protected]
Jennifer M. Scalici
Principal Investigator
CTCA at Western Regional Medical Center
Goodyear Arizona, 85338, United States More Info
Site Public Contact
Contact
623-207-3000
Sagun Shrestha
Principal Investigator
Kingman Regional Medical Center
Kingman Arizona, 86401, United States More Info
Site Public Contact
Contact
702-384-0013
[email protected]
John A. Ellerton
Principal Investigator
PCR Oncology
Arroyo Grande California, 93420, United States More Info
Site Public Contact
Contact
702-384-0013
[email protected]
John A. Ellerton
Principal Investigator
Saint Joseph Hospital - Orange
Orange California, 92868, United States More Info
Site Public Contact
Contact
714-734-6220
Timothy E. Byun
Principal Investigator
UM Sylvester Comprehensive Cancer Center at Aventura
Aventura Florida, 33180, United States More Info
Site Public Contact
Contact
954-461-2180
Chukwuemeka (Emeka) V. Ikpeazu
Principal Investigator
UM Sylvester Comprehensive Cancer Center at Coral Gables
Coral Gables Florida, 33146, United States More Info
Site Public Contact
Contact
305-243-2647
Chukwuemeka (Emeka) V. Ikpeazu
Principal Investigator
UM Sylvester Comprehensive Cancer Center at Deerfield Beach
Deerfield Beach Florida, 33442, United States More Info
Site Public Contact
Contact
305-243-2647
Chukwuemeka (Emeka) V. Ikpeazu
Principal Investigator
University of Miami Miller School of Medicine-Sylvester Cancer Center
Miami Florida, 33136, United States More Info
Site Public Contact
Contact
305-243-2647
Chukwuemeka (Emeka) V. Ikpeazu
Principal Investigator
UM Sylvester Comprehensive Cancer Center at Kendall
Miami Florida, 33176, United States More Info
Site Public Contact
Contact
305-243-2647
Chukwuemeka (Emeka) V. Ikpeazu
Principal Investigator
UM Sylvester Comprehensive Cancer Center at Plantation
Plantation Florida, 33324, United States More Info
Site Public Contact
Contact
305-243-2647
Chukwuemeka (Emeka) V. Ikpeazu
Principal Investigator
Queen's Cancer Cenrer - POB I
Honolulu Hawaii, 96813, United States More Info
Site Public Contact
Contact
808-532-0315
Michael E. Carney
Principal Investigator
Queen's Medical Center
Honolulu Hawaii, 96813, United States More Info
Site Public Contact
Contact
808-545-8548
Michael E. Carney
Principal Investigator
Queen's Cancer Center - Kuakini
Honolulu Hawaii, 96817, United States More Info
Site Public Contact
Contact
808-531-8521
Michael E. Carney
Principal Investigator
Kapiolani Medical Center for Women and Children
Honolulu Hawaii, 96826, United States More Info
Site Public Contact
Contact
808-983-6090
Michael E. Carney
Principal Investigator
Saint Alphonsus Cancer Care Center-Boise
Boise Idaho, 83706, United States
Saint Luke's Cancer Institute - Boise
Boise Idaho, 83712, United States More Info
Site Public Contact
Contact
208-381-2774
[email protected]
Nitya Alluri
Principal Investigator
Saint Alphonsus Cancer Care Center-Caldwell
Caldwell Idaho, 83605, United States
Kootenai Health - Coeur d'Alene
Coeur d'Alene Idaho, 83814, United States More Info
Site Public Contact
Contact
406-969-6060
[email protected]
John M. Schallenkamp
Principal Investigator
Saint Luke's Cancer Institute - Fruitland
Fruitland Idaho, 83619, United States More Info
Site Public Contact
Contact
208-381-2774
[email protected]
Nitya Alluri
Principal Investigator
Saint Luke's Cancer Institute - Meridian
Meridian Idaho, 83642, United States More Info
Site Public Contact
Contact
208-381-2774
[email protected]
Nitya Alluri
Principal Investigator
Saint Luke's Cancer Institute - Nampa
Nampa Idaho, 83686, United States More Info
Site Public Contact
Contact
208-381-2774
[email protected]
Nitya Alluri
Principal Investigator
Saint Alphonsus Cancer Care Center-Nampa
Nampa Idaho, 83687, United States
Kootenai Clinic Cancer Services - Post Falls
Post Falls Idaho, 83854, United States More Info
Site Public Contact
Contact
406-969-6060
[email protected]
John M. Schallenkamp
Principal Investigator
Kootenai Cancer Clinic
Sandpoint Idaho, 83864, United States More Info
Site Public Contact
Contact
406-969-6060
[email protected]
John M. Schallenkamp
Principal Investigator
Saint Luke's Cancer Institute - Twin Falls
Twin Falls Idaho, 83301, United States More Info
Site Public Contact
Contact
208-381-2774
[email protected]
Nitya Alluri
Principal Investigator
Advocate Good Shepherd Hospital
Barrington Illinois, 60010, United States More Info
Site Public Contact
Contact
847-842-4847
Antony Ruggeri
Principal Investigator
Illinois CancerCare-Bloomington
Bloomington Illinois, 61704, United States More Info
Site Public Contact
Contact
309-243-3605
[email protected]
Bryan A. Faller
Principal Investigator
Illinois CancerCare-Canton
Canton Illinois, 61520, United States More Info
Site Public Contact
Contact
309-243-3605
[email protected]
Bryan A. Faller
Principal Investigator
Illinois CancerCare-Carthage
Carthage Illinois, 62321, United States More Info
Site Public Contact
Contact
309-243-3605
[email protected]
Bryan A. Faller
Principal Investigator
Centralia Oncology Clinic
Centralia Illinois, 62801, United States More Info
Site Public Contact
Contact
217-876-4762
[email protected]
Bryan A. Faller
Principal Investigator
John H Stroger Jr Hospital of Cook County
Chicago Illinois, 60612, United States More Info
Site Public Contact
Contact
312-864-5204
Thomas E. Lad
Principal Investigator
University of Chicago Comprehensive Cancer Center
Chicago Illinois, 60637, United States More Info
Site Public Contact
Contact
773-702-8222
[email protected]
Katherine C. Kurnit
Principal Investigator
Advocate Illinois Masonic Medical Center
Chicago Illinois, 60657, United States More Info
Site Public Contact
Contact
773-296-5360
Antony Ruggeri
Principal Investigator
AMG Crystal Lake - Oncology
Crystal Lake Illinois, 60014, United States More Info
Site Public Contact
Contact
630-929-6129
[email protected]
Antony Ruggeri
Principal Investigator
Carle at The Riverfront
Danville Illinois, 61832, United States More Info
Site Public Contact
Contact
800-446-5532
[email protected]
Georgina Cheng
Principal Investigator
Cancer Care Specialists of Illinois - Decatur
Decatur Illinois, 62526, United States More Info
Site Public Contact
Contact
217-876-4762
[email protected]
Bryan A. Faller
Principal Investigator
Decatur Memorial Hospital
Decatur Illinois, 62526, United States More Info
Site Public Contact
Contact
217-876-4762
[email protected]
Bryan A. Faller
Principal Investigator
Illinois CancerCare-Dixon
Dixon Illinois, 61021, United States More Info
Site Public Contact
Contact
815-285-7800
Bryan A. Faller
Principal Investigator
Advocate Good Samaritan Hospital
Downers Grove Illinois, 60515, United States More Info
Site Public Contact
Contact
630-275-1270
[email protected]
Antony Ruggeri
Principal Investigator
Carle Physician Group-Effingham
Effingham Illinois, 62401, United States More Info
Site Public Contact
Contact
800-446-5532
[email protected]
Georgina Cheng
Principal Investigator
Crossroads Cancer Center
Effingham Illinois, 62401, United States More Info
Site Public Contact
Contact
217-876-4762
[email protected]
Bryan A. Faller
Principal Investigator
Advocate Sherman Hospital
Elgin Illinois, 60123, United States More Info
Site Public Contact
Contact
847-429-2907
Antony Ruggeri
Principal Investigator
Illinois CancerCare-Eureka
Eureka Illinois, 61530, United States More Info
Site Public Contact
Contact
309-243-3605
[email protected]
Bryan A. Faller
Principal Investigator
Illinois CancerCare-Galesburg
Galesburg Illinois, 61401, United States More Info
Site Public Contact
Contact
309-243-3605
[email protected]
Bryan A. Faller
Principal Investigator
Advocate South Suburban Hospital
Hazel Crest Illinois, 60429, United States More Info
Site Public Contact
Contact
708-799-9995
Antony Ruggeri
Principal Investigator
Illinois CancerCare-Kewanee Clinic
Kewanee Illinois, 61443, United States More Info
Site Public Contact
Contact
309-243-3605
[email protected]
Bryan A. Faller
Principal Investigator
AMG Libertyville - Oncology
Libertyville Illinois, 60048, United States More Info
Site Public Contact
Contact
630-929-6129
[email protected]
Antony Ruggeri
Principal Investigator
Condell Memorial Hospital
Libertyville Illinois, 60048, United States More Info
Site Public Contact
Contact
630-929-6129
[email protected]
Antony Ruggeri
Principal Investigator
Illinois CancerCare-Macomb
Macomb Illinois, 61455, United States More Info
Site Public Contact
Contact
309-243-3605
[email protected]
Bryan A. Faller
Principal Investigator
Carle Physician Group-Mattoon/Charleston
Mattoon Illinois, 61938, United States More Info
Site Public Contact
Contact
800-446-5532
[email protected]
Georgina Cheng
Principal Investigator
UC Comprehensive Cancer Center at Silver Cross
New Lenox Illinois, 60451, United States More Info
Site Public Contact
Contact
773-702-8222
[email protected]
Katherine C. Kurnit
Principal Investigator
Cancer Care Center of O'Fallon
O'Fallon Illinois, 62269, United States More Info
Site Public Contact
Contact
217-876-4762
[email protected]
Bryan A. Faller
Principal Investigator
Advocate Christ Medical Center
Oak Lawn Illinois, 60453, United States More Info
Site Public Contact
Contact
800-323-8622
Antony Ruggeri
Principal Investigator
University of Chicago Medicine-Orland Park
Orland Park Illinois, 60462, United States More Info
Site Public Contact
Contact
773-702-8222
[email protected]
Katherine C. Kurnit
Principal Investigator
Illinois CancerCare-Ottawa Clinic
Ottawa Illinois, 61350, United States More Info
Site Public Contact
Contact
309-243-3605
[email protected]
Bryan A. Faller
Principal Investigator
Advocate Lutheran General Hospital
Park Ridge Illinois, 60068, United States More Info
Site Public Contact
Contact
847-384-3621
Antony Ruggeri
Principal Investigator
Illinois CancerCare-Pekin
Pekin Illinois, 61554, United States More Info
Site Public Contact
Contact
309-243-3605
[email protected]
Bryan A. Faller
Principal Investigator
Illinois CancerCare-Peoria
Peoria Illinois, 61615, United States More Info
Site Public Contact
Contact
309-243-3605
[email protected]
Bryan A. Faller
Principal Investigator
Illinois CancerCare-Peru
Peru Illinois, 61354, United States More Info
Site Public Contact
Contact
309-243-3605
[email protected]
Bryan A. Faller
Principal Investigator
Illinois CancerCare-Princeton
Princeton Illinois, 61356, United States More Info
Site Public Contact
Contact
309-243-3605
[email protected]
Bryan A. Faller
Principal Investigator
Southern Illinois University School of Medicine
Springfield Illinois, 62702, United States More Info
Site Public Contact
Contact
217-545-7929
Bryan A. Faller
Principal Investigator
Springfield Clinic
Springfield Illinois, 62702, United States More Info
Site Public Contact
Contact
800-444-7541
Bryan A. Faller
Principal Investigator
Memorial Medical Center
Springfield Illinois, 62781, United States More Info
Site Public Contact
Contact
217-528-7541
[email protected]
Bryan A. Faller
Principal Investigator
Carle Cancer Center
Urbana Illinois, 61801, United States More Info
Site Public Contact
Contact
800-446-5532
[email protected]
Georgina Cheng
Principal Investigator
Illinois CancerCare - Washington
Washington Illinois, 61571, United States More Info
Site Public Contact
Contact
309-243-3605
[email protected]
Bryan A. Faller
Principal Investigator
Mission Cancer and Blood - Ankeny
Ankeny Iowa, 50023, United States More Info
Site Public Contact
Contact
515-282-2921
Joshua Lukenbill
Principal Investigator
Medical Oncology and Hematology Associates-Des Moines
Des Moines Iowa, 50309, United States More Info
Site Public Contact
Contact
515-241-3305
Joshua Lukenbill
Principal Investigator
University of Kentucky/Markey Cancer Center
Lexington Kentucky, 40536, United States More Info
Site Public Contact
Contact
859-257-3379
Susanne M. Arnold
Principal Investigator
Ochsner Baptist Medical Center
New Orleans Louisiana, 70115, United States More Info
Site Public Contact
Contact
504-842-8084
[email protected]
Katrina S. Wade
Principal Investigator
Ochsner Medical Center Jefferson
New Orleans Louisiana, 70121, United States More Info
Site Public Contact
Contact
504-842-8084
[email protected]
Katrina S. Wade
Principal Investigator
Lafayette Family Cancer Center-EMMC
Brewer Maine, 04412, United States More Info
Site Public Contact
Contact
800-987-3005
Sarah J. Sinclair
Principal Investigator
Maine Medical Center- Scarborough Campus
Scarborough Maine, 04074, United States More Info
Site Public Contact
Contact
207-396-8090
[email protected]
Leslie S. Bradford
Principal Investigator
National Institutes of Health Clinical Center
Bethesda Maryland, 20892, United States More Info
Site Public Contact
Contact
800-411-1222
A P. Chen
Principal Investigator
UPMC Western Maryland
Cumberland Maryland, 21502, United States More Info
Site Public Contact
Contact
240-964-1400
Alexander B. Olawaiye
Principal Investigator
Baystate Medical Center
Springfield Massachusetts, 01199, United States More Info
Site Public Contact
Contact
413-794-3565
[email protected]
Tashanna K. Myers
Principal Investigator
Saint Joseph Mercy Hospital
Ann Arbor Michigan, 48106, United States More Info
Site Public Contact
Contact
734-712-7251
[email protected]
Tareq Al Baghdadi
Principal Investigator
Saint Joseph Mercy Brighton
Brighton Michigan, 48114, United States More Info
Site Public Contact
Contact
734-712-7251
[email protected]
Tareq Al Baghdadi
Principal Investigator
Trinity Health IHA Medical Group Hematology Oncology - Brighton
Brighton Michigan, 48114, United States More Info
Site Public Contact
Contact
734-712-7251
[email protected]
Tareq Al Baghdadi
Principal Investigator
Saint Joseph Mercy Canton
Canton Michigan, 48188, United States More Info
Site Public Contact
Contact
734-712-7251
[email protected]
Tareq Al Baghdadi
Principal Investigator
Trinity Health IHA Medical Group Hematology Oncology - Canton
Canton Michigan, 48188, United States More Info
Site Public Contact
Contact
734-712-7251
[email protected]
Tareq Al Baghdadi
Principal Investigator
Saint Joseph Mercy Chelsea
Chelsea Michigan, 48118, United States More Info
Site Public Contact
Contact
734-712-7251
[email protected]
Tareq Al Baghdadi
Principal Investigator
Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital
Chelsea Michigan, 48118, United States More Info
Site Public Contact
Contact
734-712-7251
[email protected]
Tareq Al Baghdadi
Principal Investigator
Beaumont Hospital - Dearborn
Dearborn Michigan, 48124, United States More Info
Site Public Contact
Contact
248-551-7695
Dana Zakalik
Principal Investigator
Beaumont Hospital - Farmington Hills
Farmington Hills Michigan, 48336, United States More Info
Site Public Contact
Contact
248-551-7695
Dana Zakalik
Principal Investigator
Genesee Cancer and Blood Disease Treatment Center
Flint Michigan, 48503, United States More Info
Site Public Contact
Contact
810-762-8038
[email protected]
Tareq Al Baghdadi
Principal Investigator
Genesee Hematology Oncology PC
Flint Michigan, 48503, United States More Info
Site Public Contact
Contact
810-762-8038
[email protected]
Tareq Al Baghdadi
Principal Investigator
Genesys Hurley Cancer Institute
Flint Michigan, 48503, United States More Info
Site Public Contact
Contact
810-762-8038
[email protected]
Tareq Al Baghdadi
Principal Investigator
Hurley Medical Center
Flint Michigan, 48503, United States More Info
Site Public Contact
Contact
810-762-8038
[email protected]
Tareq Al Baghdadi
Principal Investigator
University of Michigan Health - Sparrow Lansing
Lansing Michigan, 48912, United States More Info
Site Public Contact
Contact
517-364-3712
[email protected]
Tareq Al Baghdadi
Principal Investigator
Trinity Health Saint Mary Mercy Livonia Hospital
Livonia Michigan, 48154, United States More Info
Site Public Contact
Contact
734-712-7251
[email protected]
Tareq Al Baghdadi
Principal Investigator
Great Lakes Cancer Management Specialists-Macomb Medical Campus
Macomb Michigan, 48044, United States More Info
Site Public Contact
Contact
313-343-3166
[email protected]
Tareq Al Baghdadi
Principal Investigator
William Beaumont Hospital-Royal Oak
Royal Oak Michigan, 48073, United States More Info
Site Public Contact
Contact
248-551-7695
Dana Zakalik
Principal Investigator
William Beaumont Hospital - Troy
Troy Michigan, 48085, United States More Info
Site Public Contact
Contact
248-551-7695
Dana Zakalik
Principal Investigator
Huron Gastroenterology PC
Ypsilanti Michigan, 48106, United States More Info
Site Public Contact
Contact
734-712-7251
[email protected]
Tareq Al Baghdadi
Principal Investigator
Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus
Ypsilanti Michigan, 48197, United States More Info
Site Public Contact
Contact
734-712-7251
[email protected]
Tareq Al Baghdadi
Principal Investigator
Mercy Hospital
Coon Rapids Minnesota, 55433, United States More Info
Site Public Contact
Contact
952-993-1517
[email protected]
Yan Ji
Principal Investigator
Essentia Health - Deer River Clinic
Deer River Minnesota, 56636, United States More Info
Site Public Contact
Contact
218-786-3308
[email protected]
Bret E. Friday
Principal Investigator
Essentia Health Cancer Center
Duluth Minnesota, 55805, United States More Info
Site Public Contact
Contact
218-786-3308
[email protected]
Bret E. Friday
Principal Investigator
Fairview Southdale Hospital
Edina Minnesota, 55435, United States More Info
Site Public Contact
Contact
952-993-1517
[email protected]
Yan Ji
Principal Investigator
Essentia Health Hibbing Clinic
Hibbing Minnesota, 55746, United States More Info
Site Public Contact
Contact
218-786-3308
Bret E. Friday
Principal Investigator
Abbott-Northwestern Hospital
Minneapolis Minnesota, 55407, United States More Info
Site Public Contact
Contact
952-993-1517
[email protected]
Yan Ji
Principal Investigator
Mayo Clinic in Rochester
Rochester Minnesota, 55905, United States More Info
Site Public Contact
Contact
855-776-0015
Grace M. Choong
Principal Investigator
Park Nicollet Clinic - Saint Louis Park
Saint Louis Park Minnesota, 55416, United States More Info
Site Public Contact
Contact
952-993-1517
[email protected]
Yan Ji
Principal Investigator
Regions Hospital
Saint Paul Minnesota, 55101, United States More Info
Site Public Contact
Contact
952-993-1517
[email protected]
Yan Ji
Principal Investigator
United Hospital
Saint Paul Minnesota, 55102, United States More Info
Site Public Contact
Contact
952-993-1517
[email protected]
Yan Ji
Principal Investigator
Essentia Health Sandstone
Sandstone Minnesota, 55072, United States More Info
Site Public Contact
Contact
218-786-3308
[email protected]
Bret E. Friday
Principal Investigator
Essentia Health Virginia Clinic
Virginia Minnesota, 55792, United States More Info
Site Public Contact
Contact
218-786-3308
[email protected]
Bret E. Friday
Principal Investigator
Saint Francis Medical Center
Cape Girardeau Missouri, 63703, United States More Info
Site Public Contact
Contact
573-334-2230
[email protected]
Bryan A. Faller
Principal Investigator
Washington University School of Medicine
Saint Louis Missouri, 63110, United States More Info
Site Public Contact
Contact
800-600-3606
[email protected]
Premal H. Thaker
Principal Investigator
Community Hospital of Anaconda
Anaconda Montana, 59711, United States More Info
Site Public Contact
Contact
406-969-6060
[email protected]
John M. Schallenkamp
Principal Investigator
Billings Clinic Cancer Center
Billings Montana, 59101, United States More Info
Site Public Contact
Contact
800-996-2663
[email protected]
John M. Schallenkamp
Principal Investigator
Bozeman Deaconess Hospital
Bozeman Montana, 59715, United States More Info
Site Public Contact
Contact
406-969-6060
[email protected]
John M. Schallenkamp
Principal Investigator
Benefis Healthcare- Sletten Cancer Institute
Great Falls Montana, 59405, United States More Info
Site Public Contact
Contact
406-969-6060
[email protected]
John M. Schallenkamp
Principal Investigator
Kalispell Regional Medical Center
Kalispell Montana, 59901, United States More Info
Site Public Contact
Contact
406-969-6060
[email protected]
John M. Schallenkamp
Principal Investigator
Community Medical Hospital
Missoula Montana, 59804, United States More Info
Site Public Contact
Contact
406-969-6060
[email protected]
John M. Schallenkamp
Principal Investigator
OptumCare Cancer Care at Charleston
Las Vegas Nevada, 89102, United States More Info
Site Public Contact
Contact
702-384-0013
[email protected]
John A. Ellerton
Principal Investigator
OptumCare Cancer Care at Fort Apache
Las Vegas Nevada, 89148, United States More Info
Site Public Contact
Contact
702-384-0013
[email protected]
John A. Ellerton
Principal Investigator
Memorial Sloan Kettering Monmouth
Middletown New Jersey, 07748, United States More Info
Site Public Contact
Contact
212-639-7592
Claire F. Friedman
Principal Investigator
Sidney Kimmel Cancer Center Washington Township
Sewell New Jersey, 08080, United States More Info
Site Public Contact
Contact
215-600-9151
[email protected]
Mitchell I. Edelson
Principal Investigator
University of New Mexico Cancer Center
Albuquerque New Mexico, 87102, United States More Info
Site Public Contact
Contact
505-925-0348
[email protected]
Carolyn Y. Muller
Principal Investigator
Roswell Park Cancer Institute
Buffalo New York, 14263, United States More Info
Site Public Contact
Contact
800-767-9355
[email protected]
Ellis G. Levine
Principal Investigator
Memorial Sloan Kettering Commack
Commack New York, 11725, United States More Info
Site Public Contact
Contact
212-639-7592
Claire F. Friedman
Principal Investigator
Memorial Sloan Kettering Westchester
Harrison New York, 10604, United States More Info
Site Public Contact
Contact
212-639-7592
Claire F. Friedman
Principal Investigator
Memorial Sloan Kettering Cancer Center
New York New York, 10065, United States More Info
Site Public Contact
Contact
212-639-7592
Claire F. Friedman
Principal Investigator
State University of New York Upstate Medical University
Syracuse New York, 13210, United States More Info
Site Public Contact
Contact
315-464-5476
Mary J. Cunningham
Principal Investigator
Duke University Medical Center
Durham North Carolina, 27710, United States More Info
Site Public Contact
Contact
888-275-3853
Angeles A. Secord
Principal Investigator
Duke Women's Cancer Care Raleigh
Raleigh North Carolina, 27607, United States More Info
Site Public Contact
Contact
919-785-4878
Angeles A. Secord
Principal Investigator
Sanford Broadway Medical Center
Fargo North Dakota, 58122, United States More Info
Site Public Contact
Contact
701-323-5760
[email protected]
Maria C. Bell
Principal Investigator
Sanford Roger Maris Cancer Center
Fargo North Dakota, 58122, United States More Info
Site Public Contact
Contact
701-234-6161
[email protected]
Maria C. Bell
Principal Investigator
UH Seidman Cancer Center at UH Avon Health Center
Avon Ohio, 44011, United States More Info
Site Public Contact
Contact
800-641-2422
Alberto J. Montero
Principal Investigator
UHHS-Chagrin Highlands Medical Center
Beachwood Ohio, 44122, United States More Info
Site Public Contact
Contact
800-641-2422
[email protected]
Alberto J. Montero
Principal Investigator
Strecker Cancer Center-Belpre
Belpre Ohio, 45714, United States More Info
Site Public Contact
Contact
614-488-2745
[email protected]
Timothy D. Moore
Principal Investigator
Aultman Health Foundation
Canton Ohio, 44710, United States More Info
Site Public Contact
Contact
330-363-7274
[email protected]
Adarsh Vennepureddy
Principal Investigator
Miami Valley Hospital South
Centerville Ohio, 45459, United States More Info
Site Public Contact
Contact
937-528-2900
[email protected]
Michael S. Guy
Principal Investigator
Adena Regional Medical Center
Chillicothe Ohio, 45601, United States More Info
Site Public Contact
Contact
877-779-7585
[email protected]
Timothy D. Moore
Principal Investigator
Case Western Reserve University
Cleveland Ohio, 44106, United States More Info
Site Public Contact
Contact
800-641-2422
[email protected]
Alberto J. Montero
Principal Investigator
Ohio State University Comprehensive Cancer Center
Columbus Ohio, 43210, United States More Info
Site Public Contact
Contact
800-293-5066
[email protected]
Floor Backes
Principal Investigator
Mount Carmel East Hospital
Columbus Ohio, 43213, United States More Info
Site Public Contact
Contact
614-488-2745
[email protected]
Timothy D. Moore
Principal Investigator
The Mark H Zangmeister Center
Columbus Ohio, 43219, United States More Info
Site Public Contact
Contact
614-488-2745
[email protected]
Timothy D. Moore
Principal Investigator
Dayton Physician LLC-Miami Valley Hospital North
Dayton Ohio, 45415, United States More Info
Site Public Contact
Contact
937-528-2900
[email protected]
Howard M. Gross
Principal Investigator
Kettering Medical Center
Kettering Ohio, 45429, United States More Info
Site Public Contact
Contact
937-528-2900
[email protected]
Howard M. Gross
Principal Investigator
Fairfield Medical Center
Lancaster Ohio, 43130, United States More Info
Site Public Contact
Contact
614-488-2745
[email protected]
Timothy D. Moore
Principal Investigator
Marietta Memorial Hospital
Marietta Ohio, 45750, United States More Info
Site Public Contact
Contact
614-488-2745
[email protected]
Timothy D. Moore
Principal Investigator
Memorial Hospital
Marysville Ohio, 43040, United States More Info
Site Public Contact
Contact
614-488-2745
[email protected]
Timothy D. Moore
Principal Investigator
UH Seidman Cancer Center at Lake Health Mentor Campus
Mentor Ohio, 44060, United States More Info
Site Public Contact
Contact
800-641-2422
[email protected]
Alberto J. Montero
Principal Investigator
Knox Community Hospital
Mount Vernon Ohio, 43050, United States More Info
Site Public Contact
Contact
614-488-2745
[email protected]
Timothy D. Moore
Principal Investigator
Licking Memorial Hospital
Newark Ohio, 43055, United States More Info
Site Public Contact
Contact
614-488-2745
[email protected]
Timothy D. Moore
Principal Investigator
Mercy Health Perrysburg Cancer Center
Perrysburg Ohio, 43551, United States More Info
Site Public Contact
Contact
614-488-2745
[email protected]
Timothy D. Moore
Principal Investigator
Southern Ohio Medical Center
Portsmouth Ohio, 45662, United States More Info
Site Public Contact
Contact
614-488-2745
[email protected]
Timothy D. Moore
Principal Investigator
Springfield Regional Cancer Center
Springfield Ohio, 45504, United States More Info
Site Public Contact
Contact
614-488-2745
[email protected]
Timothy D. Moore
Principal Investigator
Springfield Regional Medical Center
Springfield Ohio, 45505, United States More Info
Site Public Contact
Contact
614-488-2745
[email protected]
Timothy D. Moore
Principal Investigator
Mercy Health - Saint Anne Hospital
Toledo Ohio, 43623, United States More Info
Site Public Contact
Contact
614-488-2745
[email protected]
Timothy D. Moore
Principal Investigator
Saint Ann's Hospital
Westerville Ohio, 43081, United States More Info
Site Public Contact
Contact
614-488-2745
[email protected]
Timothy D. Moore
Principal Investigator
Genesis Healthcare System Cancer Care Center
Zanesville Ohio, 43701, United States More Info
Site Public Contact
Contact
614-488-2745
[email protected]
Timothy D. Moore
Principal Investigator
University of Oklahoma Health Sciences Center
Oklahoma City Oklahoma, 73104, United States More Info
Site Public Contact
Contact
405-271-8777
[email protected]
Lauren E. Dockery
Principal Investigator
Providence Newberg Medical Center
Newberg Oregon, 97132, United States More Info
Site Public Contact
Contact
503-215-2614
[email protected]
Nitya Alluri
Principal Investigator
Saint Alphonsus Medical Center-Ontario
Ontario Oregon, 97914, United States
Providence Willamette Falls Medical Center
Oregon City Oregon, 97045, United States More Info
Site Public Contact
Contact
503-215-2614
[email protected]
Nitya Alluri
Principal Investigator
Providence Portland Medical Center
Portland Oregon, 97213, United States More Info
Site Public Contact
Contact
503-215-2614
[email protected]
Nitya Alluri
Principal Investigator
Providence Saint Vincent Medical Center
Portland Oregon, 97225, United States More Info
Site Public Contact
Contact
503-215-2614
[email protected]
Nitya Alluri
Principal Investigator
Lehigh Valley Hospital-Cedar Crest
Allentown Pennsylvania, 18103, United States More Info
Site Public Contact
Contact
610-402-9543
[email protected]
Tareq Al Baghdadi
Principal Investigator
UPMC Altoona
Altoona Pennsylvania, 16601, United States More Info
Site Public Contact
Contact
412-339-5294
[email protected]
Alexander B. Olawaiye
Principal Investigator
Lehigh Valley Hospital - Muhlenberg
Bethlehem Pennsylvania, 18017, United States More Info
Site Public Contact
Contact
610-402-9543
[email protected]
Tareq Al Baghdadi
Principal Investigator
Bryn Mawr Hospital
Bryn Mawr Pennsylvania, 19010, United States More Info
Site Public Contact
Contact
484-476-2649
[email protected]
Paul B. Gilman
Principal Investigator
Pocono Medical Center
East Stroudsburg Pennsylvania, 18301, United States More Info
Site Public Contact
Contact
610-402-9543
[email protected]
Tareq Al Baghdadi
Principal Investigator
UPMC Hillman Cancer Center Erie
Erie Pennsylvania, 16505, United States More Info
Site Public Contact
Contact
412-389-5208
[email protected]
Alexander B. Olawaiye
Principal Investigator
UPMC Cancer Centers - Arnold Palmer Pavilion
Greensburg Pennsylvania, 15601, United States More Info
Site Public Contact
Contact
724-838-1900
Alexander B. Olawaiye
Principal Investigator
UPMC Hillman Cancer Center at Rocco And Nancy Ortenzio Cancer Pavilion
Mechanicsburg Pennsylvania, 17050, United States More Info
Site Public Contact
Contact
412-389-5208
[email protected]
Alexander B. Olawaiye
Principal Investigator
Riddle Memorial Hospital
Media Pennsylvania, 19063, United States More Info
Site Public Contact
Contact
484-476-2649
[email protected]
Paul B. Gilman
Principal Investigator
UPMC Hillman Cancer Center - Monroeville
Monroeville Pennsylvania, 15146, United States More Info
Site Public Contact
Contact
412-389-5208
[email protected]
Alexander B. Olawaiye
Principal Investigator
Paoli Memorial Hospital
Paoli Pennsylvania, 19301, United States More Info
Site Public Contact
Contact
484-476-2649
[email protected]
Paul B. Gilman
Principal Investigator
Thomas Jefferson University Hospital
Philadelphia Pennsylvania, 19107, United States More Info
Site Public Contact
Contact
215-600-9151
[email protected]
Mitchell I. Edelson
Principal Investigator
University of Pittsburgh Cancer Institute (UPCI)
Pittsburgh Pennsylvania, 15232, United States More Info
Site Public Contact
Contact
412-647-8073
Alexander B. Olawaiye
Principal Investigator
UPMC-Passavant Hospital
Pittsburgh Pennsylvania, 15237, United States More Info
Site Public Contact
Contact
412-367-6454
Alexander B. Olawaiye
Principal Investigator
Asplundh Cancer Pavilion
Willow Grove Pennsylvania, 19090, United States More Info
Site Public Contact
Contact
215-600-9151
[email protected]
Mitchell I. Edelson
Principal Investigator
Lankenau Medical Center
Wynnewood Pennsylvania, 19096, United States More Info
Site Public Contact
Contact
484-476-2649
[email protected]
Paul B. Gilman
Principal Investigator
Women and Infants Hospital
Providence Rhode Island, 02905, United States More Info
Site Public Contact
Contact
401-274-1122
Matthew T. Oliver
Principal Investigator
Sanford Cancer Center Oncology Clinic
Sioux Falls South Dakota, 57104, United States More Info
Site Public Contact
Contact
605-312-3320
[email protected]
Maria C. Bell
Principal Investigator
Sanford USD Medical Center - Sioux Falls
Sioux Falls South Dakota, 57117, United States More Info
Site Public Contact
Contact
605-312-3320
[email protected]
Maria C. Bell
Principal Investigator
MD Anderson in The Woodlands
Conroe Texas, 77384, United States More Info
Site Public Contact
Contact
866-632-6789
[email protected]
Shannon N. Westin
Principal Investigator
M D Anderson Cancer Center
Houston Texas, 77030, United States More Info
Site Public Contact
Contact
877-632-6789
[email protected]
Shannon N. Westin
Principal Investigator
MD Anderson West Houston
Houston Texas, 77079, United States More Info
Site Public Contact
Contact
877-632-6789
[email protected]
Shannon N. Westin
Principal Investigator
MD Anderson League City
League City Texas, 77573, United States More Info
Site Public Contact
Contact
877-632-6789
[email protected]
Shannon N. Westin
Principal Investigator
MD Anderson in Sugar Land
Sugar Land Texas, 77478, United States More Info
Site Public Contact
Contact
877-632-6789
[email protected]
Shannon N. Westin
Principal Investigator
Virginia Cancer Institute
Richmond Virginia, 23229, United States More Info
Site Public Contact
Contact
804-287-3000
[email protected]
Leslie M. Randall
Principal Investigator
VCU Massey Cancer Center at Stony Point
Richmond Virginia, 23235, United States More Info
Site Public Contact
Contact
[email protected]
Leslie M. Randall
Principal Investigator
Virginia Commonwealth University/Massey Cancer Center
Richmond Virginia, 23298, United States More Info
Site Public Contact
Contact
[email protected]
Leslie M. Randall
Principal Investigator
VCU Community Memorial Health Center
South Hill Virginia, 23970, United States More Info
Site Public Contact
Contact
[email protected]
Leslie M. Randall
Principal Investigator
Swedish Cancer Institute-Edmonds
Edmonds Washington, 98026, United States More Info
Site Public Contact
Contact
206-215-3086
[email protected]
Nitya Alluri
Principal Investigator
Swedish Cancer Institute-Issaquah
Issaquah Washington, 98029, United States More Info
Site Public Contact
Contact
206-215-3086
[email protected]
Nitya Alluri
Principal Investigator
Valley Medical Center
Renton Washington, 98055, United States More Info
Site Public Contact
Contact
425-228-3440
[email protected]
John A. Ellerton
Principal Investigator
Swedish Medical Center-First Hill
Seattle Washington, 98122, United States More Info
Site Public Contact
Contact
206-215-3086
[email protected]
Nitya Alluri
Principal Investigator
North Star Lodge Cancer Center at Yakima Valley Memorial Hospital
Yakima Washington, 98902, United States More Info
Site Public Contact
Contact
509-574-3535
[email protected]
John A. Ellerton
Principal Investigator
Edwards Comprehensive Cancer Center
Huntington West Virginia, 25701, United States More Info
Site Public Contact
Contact
304-399-6566
[email protected]
Maria R. Tria Tirona
Principal Investigator
West Virginia University Healthcare
Morgantown West Virginia, 26506, United States More Info
Site Public Contact
Contact
304-293-7374
[email protected]
Krista S. Pfaendler
Principal Investigator
Duluth Clinic Ashland
Ashland Wisconsin, 54806, United States More Info
Site Public Contact
Contact
218-786-3308
[email protected]
Bret E. Friday
Principal Investigator
Aurora Cancer Care-Southern Lakes VLCC
Burlington Wisconsin, 53105, United States More Info
Site Public Contact
Contact
414-302-2304
[email protected]
Antony Ruggeri
Principal Investigator
Aurora Saint Luke's South Shore
Cudahy Wisconsin, 53110, United States More Info
Site Public Contact
Contact
414-302-2304
[email protected]
Antony Ruggeri
Principal Investigator
Aurora Health Care Germantown Health Center
Germantown Wisconsin, 53022, United States More Info
Site Public Contact
Contact
414-302-2304
[email protected]
Antony Ruggeri
Principal Investigator
Aurora Cancer Care-Grafton
Grafton Wisconsin, 53024, United States More Info
Site Public Contact
Contact
414-302-2304
[email protected]
Antony Ruggeri
Principal Investigator
Aurora BayCare Medical Center
Green Bay Wisconsin, 54311, United States More Info
Site Public Contact
Contact
414-302-2304
[email protected]
Antony Ruggeri
Principal Investigator
Aurora Cancer Care-Kenosha South
Kenosha Wisconsin, 53142, United States More Info
Site Public Contact
Contact
414-302-2304
[email protected]
Antony Ruggeri
Principal Investigator
Gundersen Lutheran Medical Center
La Crosse Wisconsin, 54601, United States More Info
Site Public Contact
Contact
608-775-2385
[email protected]
Collin D. Driscoll
Principal Investigator
University of Wisconsin Carbone Cancer Center
Madison Wisconsin, 53792, United States More Info
Site Public Contact
Contact
800-622-8922
[email protected]
Janelle Sobecki
Principal Investigator
Aurora Bay Area Medical Group-Marinette
Marinette Wisconsin, 54143, United States More Info
Site Public Contact
Contact
414-302-2304
[email protected]
Antony Ruggeri
Principal Investigator
Aurora Cancer Care-Milwaukee
Milwaukee Wisconsin, 53209, United States More Info
Site Public Contact
Contact
414-302-2304
[email protected]
Antony Ruggeri
Principal Investigator
Aurora Saint Luke's Medical Center
Milwaukee Wisconsin, 53215, United States More Info
Site Public Contact
Contact
414-302-2304
[email protected]
Antony Ruggeri
Principal Investigator
Aurora Sinai Medical Center
Milwaukee Wisconsin, 53233, United States More Info
Site Public Contact
Contact
414-302-2304
[email protected]
Antony Ruggeri
Principal Investigator
Vince Lombardi Cancer Clinic - Oshkosh
Oshkosh Wisconsin, 54904, United States More Info
Site Public Contact
Contact
414-302-2304
[email protected]
Antony Ruggeri
Principal Investigator
Aurora Cancer Care-Racine
Racine Wisconsin, 53406, United States More Info
Site Public Contact
Contact
414-302-2304
[email protected]
Antony Ruggeri
Principal Investigator
Vince Lombardi Cancer Clinic-Sheboygan
Sheboygan Wisconsin, 53081, United States More Info
Site Public Contact
Contact
414-302-2304
[email protected]
Antony Ruggeri
Principal Investigator
Aurora Medical Center in Summit
Summit Wisconsin, 53066, United States More Info
Site Public Contact
Contact
414-302-2304
[email protected]
Antony Ruggeri
Principal Investigator
Vince Lombardi Cancer Clinic-Two Rivers
Two Rivers Wisconsin, 54241, United States More Info
Site Public Contact
Contact
414-302-2304
[email protected]
Antony Ruggeri
Principal Investigator
Aurora Cancer Care-Milwaukee West
Wauwatosa Wisconsin, 53226, United States More Info
Site Public Contact
Contact
414-302-2304
[email protected]
Antony Ruggeri
Principal Investigator
Aurora West Allis Medical Center
West Allis Wisconsin, 53227, United States More Info
Site Public Contact
Contact
414-302-2304
[email protected]
Antony Ruggeri
Principal Investigator
Centro Comprensivo de Cancer de UPR
San Juan , 00927, Puerto Rico More Info
Site Public Contact
Contact
412-339-5294
[email protected]
Luis J. Santos Reyes
Principal Investigator

How clear is this clinincal trial information?

Study is for people with:

Ovarian Cancer

Phase:

Phase 2

Estimated Enrollment:

165

Study ID:

NCT05554328

Recruitment Status:

Recruiting

Sponsor:


National Cancer Institute (NCI)

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.